Terms: = Kidney tumors AND JAK3, L-JAK, 3718, ENSG00000105639, P52333, JAKL, JAK-3, LJAK, JAK3_HUMAN
18 results:
1. Prognostic value of jak3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract] [Full Text] [Related]
2. Small cell variant of chromophobe renal cell carcinoma: Clinicopathologic and molecular-genetic analysis of 10 cases.
Rogala J; Kojima F; Alaghehbandan R; Ptakova N; Bravc A; Bulimbasic S; Perez Montiel D; Slisarenko M; Ali L; Kuthi L; Pivovarcikova K; Michalova K; Bartovic B; Bartos Vesela A; Dolejsova O; Michal M; Hes O
Bosn J Basic Med Sci; 2022 Jul; 22(4):531-539. PubMed ID: 35276058
[TBL] [Abstract] [Full Text] [Related]
3. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing.
Mollica V; Franceschini T; Gruppioni E; Rizzo A; Ricci C; Schiavina R; Brunocilla E; Ardizzoni A; Fiorentino M; Giunchi F; Massari F
Pathol Res Pract; 2021 Mar; 219():153350. PubMed ID: 33556910
[TBL] [Abstract] [Full Text] [Related]
4. jak3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma.
Liang F; Liang H; Li Z; Huang P
Int Immunopharmacol; 2020 Sep; 86():106706. PubMed ID: 32570038
[TBL] [Abstract] [Full Text] [Related]
5. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract] [Full Text] [Related]
6. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates jak3 and MCL-1 leading to immune dysfunction.
Gigante M; Pontrelli P; Herr W; Gigante M; D'Avenia M; Zaza G; Cavalcanti E; Accetturo M; Lucarelli G; Carrieri G; Battaglia M; Storkus WJ; Gesualdo L; Ranieri E
J Transl Med; 2016 Apr; 14():84. PubMed ID: 27063186
[TBL] [Abstract] [Full Text] [Related]
7. A novel EGFP-expressing nude mice with complete loss of lymphocytes and NK cells to study tumor-host interactions.
Gotoh K; Kariya R; Matsuda K; Hattori S; Vaeteewoottacharn K; Okada S
Biosci Trends; 2014 Aug; 8(4):202-5. PubMed ID: 25224625
[TBL] [Abstract] [Full Text] [Related]
8. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract] [Full Text] [Related]
9. Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway.
Giron-Michel J; Azzi S; Khawam K; Mortier E; Caignard A; Devocelle A; Ferrini S; Croce M; François H; Lecru L; Charpentier B; Chouaib S; Azzarone B; Eid P
PLoS One; 2012; 7(2):e31624. PubMed ID: 22363690
[TBL] [Abstract] [Full Text] [Related]
10. Tyrosine kinase expression profile in clear cell renal cell carcinoma.
Behbahani TE; Thierse C; Baumann C; Holl D; Bastian PJ; von Ruecker A; Müller SC; Ellinger J; Hauser S
World J Urol; 2012 Aug; 30(4):559-65. PubMed ID: 21969129
[TBL] [Abstract] [Full Text] [Related]
11. jak3 in clear cell renal cell carcinoma: mutational screening and clinical implications.
de Martino M; Gigante M; Cormio L; Prattichizzo C; Cavalcanti E; Gigante M; Ariano V; Netti GS; Montemurno E; Mancini V; Battaglia M; Gesualdo L; Carrieri G; Ranieri E
Urol Oncol; 2013 Aug; 31(6):930-7. PubMed ID: 21868263
[TBL] [Abstract] [Full Text] [Related]
12. jak3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.
Cavalcanti E; Gigante M; Mancini V; Battaglia M; Ditonno P; Capobianco C; Cincione RI; Selvaggi FP; Herr W; Storkus WJ; Gesualdo L; Ranieri E
J Biomed Biotechnol; 2010; 2010():935764. PubMed ID: 20339477
[TBL] [Abstract] [Full Text] [Related]
13. Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects.
Karaczyn AA; Cheng RY; Buzard GS; Hartley J; Esposito D; Kasprzak KS
Ann Clin Lab Sci; 2009; 39(3):251-62. PubMed ID: 19667409
[TBL] [Abstract] [Full Text] [Related]
14. JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism.
Wu KL; Miao H; Khan S
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1836-46. PubMed ID: 17898043
[TBL] [Abstract] [Full Text] [Related]
15. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
Antony PA; Restifo NP
J Immunother; 2005; 28(2):120-8. PubMed ID: 15725955
[TBL] [Abstract] [Full Text] [Related]
16. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract] [Full Text] [Related]
17. Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells.
Suminami Y; Kashii Y; Law JC; Lin WC; Stanson J; Reichert TE; Rabinowich H; Whiteside TL
Oncogene; 1998 Mar; 16(10):1309-17. PubMed ID: 9546432
[TBL] [Abstract] [Full Text] [Related]
18. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V; Wang Q; Riedy MC; O'Shea J; Ritz J; Cathcart MK; Rayman P; Tubbs R; Edinger M; Novick A; Bukowski R; Finke J
J Immunol; 1997 Sep; 159(6):3057-67. PubMed ID: 9300731
[TBL] [Abstract] [Full Text] [Related]
